Bank of New York Mellon
DMAC icon

Bank of New York Mellon’s DiaMedica Therapeutics DMAC Stock Holding History

Bank of New York Mellon’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$829K Buy
117,820
+6,741
+6% +$41.4K ﹤0.01% 3474
2026
Q1 		$752K Sell
111,079
-9,898
-8% -$78.4K ﹤0.01% 3385
2025
Q4 		$963K Buy
120,977
+52,036
+75% +$389K ﹤0.01% 3259
2025
Q3 		$474K Buy
68,941
+8,876
+15% +$48.1K ﹤0.01% 3630
2025
Q2 		$234K Buy
+60,065
New +$234K ﹤0.01% 3919
2024
Q2 		– Sell
-24,000
Closed -$66.5K – 4164
2024
Q1 		$66.5K Sell
24,000
-10,233
-30% -$29.7K ﹤0.01% 4066
2023
Q4 		$97.2K Sell
34,233
-384
-1% -$950 ﹤0.01% 4090
2023
Q3 		$89.3K Sell
34,617
-1,277
-4% -$4.1K ﹤0.01% 4096
2023
Q2 		$155K Sell
35,894
-168
-0.5% -$408 ﹤0.01% 4031
2023
Q1 		$55.2K Hold
36,062
– – ﹤0.01% 4177
2022
Q4 		$57K Sell
36,062
-186
-0.5% -$250 ﹤0.01% 4217
2022
Q3 		$45K Hold
36,248
– – ﹤0.01% 4342
2022
Q2 		$73K Sell
36,248
-164
-0.5% -$383 ﹤0.01% 4291
2022
Q1 		$91K Sell
36,412
-13,472
-27% -$38.2K ﹤0.01% 4422
2021
Q4 		$186K Hold
49,884
– – ﹤0.01% 4292
2021
Q3 		$200K Buy
49,884
+11,600
+30% +$44.4K ﹤0.01% 4217
2021
Q2 		$170K Sell
38,284
-2,292
-6% -$18.8K ﹤0.01% 4131
2021
Q1 		$371K Sell
40,576
-2,329
-5% -$21.8K ﹤0.01% 3833
2020
Q4 		$435K Buy
42,905
+29,433
+218% +$161K ﹤0.01% 3684
2020
Q3 		$57K Hold
13,472
– – ﹤0.01% 4007
2020
Q2 		$93K Buy
+13,472
New +$60.1K ﹤0.01% 3913

Other funds holding DMAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
MW
Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
MWM
Meridian Wealth Management Lexington, Kentucky $3.25B AUM 41% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
CFP
Catalyst Financial Partners Boston, Massachusetts $1.01B AUM 36.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's DMAC Position: Q2 2026 in Review

Bank of New York Mellon increased its DiaMedica Therapeutics (DMAC) stake by 6.1% in Q2 2026, buying an estimated $41.4K and bringing the position to 117,820 shares worth $829K. The position accounts for ﹤0.01% of the portfolio, ranked #3474.

Bank of New York Mellon first reported a position in DMAC in Q2 2020 and has held it in 21 quarters since. The position peaked at $963K in Q4 2025. 31 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Bank of New York Mellon held 117,820 shares of DiaMedica Therapeutics worth $829K as of Q2 2026.
  • Bank of New York Mellon bought 6,741 DiaMedica Therapeutics shares in Q2 2026, an estimated $41.4K.
  • DiaMedica Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3474 holding.
  • Bank of New York Mellon first reported a position in DiaMedica Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Bank of New York Mellon's DiaMedica Therapeutics position peaked at $963K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.